This brand name is authorized in Japan, United States
The drug VILTEPSO contains one active pharmaceutical ingredient (API):
|
1
Viltolarsen
UNII SXA7YP6EKX - VILTOLARSEN
|
|
Viltolarsen is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. It is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| VILTEPSO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 1900400A1025 |
| Country: US | FDA, National Drug Code | Identifier(s): 73292-011 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
